Trastuzumab deruxtecan and the evolving role of human epidermal growth factor receptor 2–targeted antibody–drug conjugates in breast and ovarian cancer
The efficacy of T-DXd represents a major advance in HER2-targeted therapy, expanding treatment beyond HER2-positive disease into a wider continuum of HER2 expression. Ongoing clinical development of next-generation ADCs aims to improve efficacy, safety, and access to precision-guided cytotoxic therapy across solid tumors.
Authors
- Jordyn Silverstein (ORCID: https://orcid.org/0000-0002-8573-7145)
- Gottfried E. Konecny (ORCID: https://orcid.org/0000-0001-6083-657X)
- Shivani K Thaker
- Aditya Bardia
Institutions
- University of California, Los Angeles (US)
- UCLA Health (US)
Publication Details
- Journal
- Current Opinion in Obstetrics & Gynecology
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1097/gco.0000000000001080
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05